Literature DB >> 9989787

IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180.

J Perriard1, F Jaunin, B Favre, L Büdinger, M Hertl, J H Saurat, L Borradori.   

Abstract

Bullous pemphigoid (BP) and gestational pemphigoid (PG) are subepidermal blistering disorders associated with autoantibodies directed against two components of hemidesmosomes: the BP antigen 180 (BP180) and the BP antigen 230 (BP230). Autoantibodies against the extracellular domain (ECD) of BP180 are thought to play an initiatory role in subepidermal blister formation. To characterize the targeted antigenic sites on BP180, we have assessed the reactivity of sera from BP and PG patients against eukaryotic recombinant proteins encompassing various portions of the ECD and the intracellular domain (ICD) of BP180. Twenty-two of 22 (100%) BP sera that immunoblotted BP180 in keratinocyte extracts, bound a mutant form consisting of the entire ECD of BP180, whereas only three of these 22 sera (14%) reacted against the ECD of BP180 lacking the NC16A membrane proximal region. Thirteen out of the 22 (59%) BP sera recognized the ICD of BP180. Circulating IgG from a representative BP patient that was affinity purified against the ECD of BP180 did not bind the ICD when reblotted, indicating that there was no antigenic cross-reactivity between the ECD and the ICD of BP180. Reactivity against the ICD of BP180 was further ascertained by immunofluorescence microscopy studies showing that nine of the 22 (41%) BP sera stained COS-7 cells expressing the ICD of BP180. Using deletion mutants of the ICD of BP180, the majority of the sera was found to recognize the central region of the ICD of BP180. Specifically, an immunodominant region was localized to an 87-amino acid segment located towards the NH2-terminus of BP180. In contrast to BP sera, five of six (83%) PG sera contained IgG that recognized exclusively the NC16A region, whereas none bound to the ICD of BP180. Together, the results indicate that in BP, autoantibody reactivity to BP180 is not exclusively restricted to the NC16A region, but that additional antigenic determinants exist on the ICD of BP180. The observed heterogeneous immune response against BP180 might reflect intramolecular epitope spreading. Because the ICD ofBP180 harbors functionally important regions, it is possible that autoantibodies against the ICD of BP180 have pathogenic significance for the progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989787     DOI: 10.1046/j.1523-1747.1999.00497.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Eosinophil infiltration in three patients with generalized atrophic benign epidermolysis bullosa from a Japanese family: molecular genetic and immunohistochemical studies.

Authors:  Masayo Nomura; Yoh-Ichiro Hamasaki; Ichiro Katayama; Kuniko Abe; Norio Niikawa; Koh-Ichiro Yoshiura
Journal:  J Hum Genet       Date:  2005-09-20       Impact factor: 3.172

3.  The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases.

Authors:  H Schumann; J Baetge; K Tasanen; F Wojnarowska; H Schäcke; D Zillikens; L Bruckner-Tuderman
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

6.  Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

Authors:  E Schmidt; B Wehr; E M Tabengwa; S Reimer; E-B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 7.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

8.  Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals.

Authors:  A Ueki; Y Isozaki; A Tomokuni; T Hatayama; H Ueki; M Kusaka; M Shiwa; H Arikuni; T Takeshita; K Morimoto
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

9.  The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice.

Authors:  Eva Oswald; Alina Sesarman; Claus-Werner Franzke; Ute Wölfle; Leena Bruckner-Tuderman; Thilo Jakob; Stefan F Martin; Cassian Sitaru
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

Review 10.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.